Natterman Noscasan (Noscapine Hydrochloride)

Noscapine hydrochloride acts centrally on the medullary cough centre. By binding to neuronal sites that modulate cough signalling, it dampens the transmission of afferent impulses that trigger the cough reflex, thereby providing cough suppression without significant bronchodilation or sedation.

The specific dose of Natterman Noscasan is determined by the prescribing clinician based on the patient’s age, weight, severity of cough, and overall health status. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for optimal symptom control.

Safety data for noscapine hydrochloride during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with opioid‑based antitussives such as codeine, noscapine offers cough relief without the typical opioid‑related risks of dependence, respiratory depression, or significant constipation. Its central mechanism provides effective suppression of dry cough while maintaining a more favourable safety profile for many patients.

Natterman Noscasan should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability.

The medication is taken orally, usually as a tablet or liquid formulation, as directed by the prescribing clinician. It should be swallowed with water and taken at the intervals prescribed, without crushing or chewing unless the specific dosage form advises otherwise.

Serious adverse events, although rare, include allergic reactions such as rash, swelling or breathing difficulty, hepatic dysfunction manifested by elevated liver enzymes or jaundice, and hematologic abnormalities like neutropenia. Patients should seek immediate medical attention if any of these symptoms develop.

Individuals with known hypersensitivity to noscapine or any excipients in the product should avoid it. It is also contraindicated in patients with severe hepatic impairment and should be used with caution in those taking other central nervous system depressants. Pediatric use should follow local regulatory guidance.